Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Dissemination Events

McMaster University

$24,991.00

High-Sensitivity Cardiac Troponin - A Canadian Viewpoint from CIHR funded studies

FY 2013-14

Summary
In 2000 the cardiology community changed the way doctors' diagnosis a heart attack. A laboratory test, cardiac troponin (cTn) test, became an important tool for doctors to make this diagnosis. Over the next 12 years, many studies (including our CIHR-funded studies) provided the evidence on when to measure cTn in the emergency room and what levels should be used to determine if a patient has had a heart attack. The importance of our work is apparent in that 4 of our studies were referenced by the latest international guideline for heart attacks [Third Universal Definition of Myocardial Infarction(MI)] published in 2012. However, as we and others were accumulating the evidence on how to use current cTn tests, the diagnostic companies were at the same time changing and improving these tests by making them more precise and able to measure smaller concentrations of the protein. This resulted in a new generation of tests, called "high-sensitivity cardiac troponin" (hs-cTn). As these are new tests, information, data and evidence is required on how to interpret them. Also, this information should be provided to doctors and laboratory professionals so that the hs-cTn tests are used appropriately to guide care. The 2012 MI guideline does not provide any help here as there was limited evidence at the time of writing. This was confirmed by the recently released Canadian Agency for Drugs and Technologies in Health report (2013) that cited the need for "...further research exploring different clinical algorithms to optimize patient and health system outcomes associated with high-sensitivity cardiac troponin testing." Within the last year several studies have been funded by CIHR and the results will soon be available. Our workshop will bring together CIHR-funded and International researchers to discuss their research findings with a goal to produce a document on hs-cTn testing that is current, evidence-based, and relevant to Canadian healthcare providers and patients.
Program
Dissemination Events
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
296284
Name
Kavsak Peter A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Dissemination Events Grants
Projecttitle
High-Sensitivity Cardiac Troponin - A Canadian Viewpoint from CIHR funded studies
Programtype2
Miscellaneous Programs
Orgnameinp2
McMaster University
Cihramount2
$24,991
Cihrequipment2
$0
Programname2
Dissemination Events
Keyworddelim
Acute Coronary Syndrome; Canadian Workshop; Diagnostic Tests; Emergency Department; Guidelines; High-Sensitivity Cardiac Troponin; Laboratories; Myocardial Infarction; Myocardial Injury; Surgery
Abstract
In 2000 the cardiology community changed the way doctors' diagnosis a heart attack. A laboratory test, cardiac troponin (cTn) test, became an important tool for doctors to make this diagnosis. Over the next 12 years, many studies (including our CIHR-funded studies) provided the evidence on when to measure cTn in the emergency room and what levels should be used to determine if a patient has had a heart attack. The importance of our work is apparent in that 4 of our studies were referenced by the latest international guideline for heart attacks [Third Universal Definition of Myocardial Infarction(MI)] published in 2012. However, as we and others were accumulating the evidence on how to use current cTn tests, the diagnostic companies were at the same time changing and improving these tests by making them more precise and able to measure smaller concentrations of the protein. This resulted in a new generation of tests, called "high-sensitivity cardiac troponin" (hs-cTn). As these are new tests, information, data and evidence is required on how to interpret them. Also, this information should be provided to doctors and laboratory professionals so that the hs-cTn tests are used appropriately to guide care. The 2012 MI guideline does not provide any help here as there was limited evidence at the time of writing. This was confirmed by the recently released Canadian Agency for Drugs and Technologies in Health report (2013) that cited the need for "...further research exploring different clinical algorithms to optimize patient and health system outcomes associated with high-sensitivity cardiac troponin testing." Within the last year several studies have been funded by CIHR and the results will soon be available. Our workshop will bring together CIHR-funded and International researchers to discuss their research findings with a goal to produce a document on hs-cTn testing that is current, evidence-based, and relevant to Canadian healthcare providers and patients.
Competitiondate
201310
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kavsak, Peter A; Worster, Andrew
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $24,991~ $0~